BBWI
Q3 2026 EPS Estimate
$0.24
Aug 27, 2026 · Reports before open
Revenue Estimate
$1.50B
FY2027E EPS$2.65
FY2028E EPS$2.84

Analyst Sentiment

Wall St. Consensus
Hold
20 analysts·High coverage
59
Score
8 Buy (40%)11 Hold (55%)1 Sell (5%)
Rating Breakdown
Strong Buy
00%
Buy
840%
Hold
1155%
Sell
15%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$19.00
-8.6%
Consensus
$22.00
+5.8%
Bull
$26.00
+25.1%
12-Month Target Range20 analysts
$19.00$22.00$26.00
Current $20.79Consensus
Current Price
$20.79
Upside to Consensus
$1.21

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-1.43%
EPS-11.13%
FY2028
Rev+1.91%
EPS+7.21%
FY2029
Rev+3.00%
EPS+9.60%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2027EFY2028EFY2029E
Revenue Avg$7.09B$7.23B$7.44B
Low$7.07B$7.12B$7.14B
High$7.14B$7.36B$7.64B
EBITDA Avg$1.60B$1.63B$1.68B
Low$1.59B$1.60B$1.61B
High$1.61B$1.66B$1.72B
EBIT Avg$1.33B$1.36B$1.40B
Low$1.33B$1.34B$1.34B
High$1.34B$1.38B$1.44B
Net Income Avg$536M$568M$615M
Low$533M$557M$601M
High$586M$675M$716M
EPS Avg$2.65$2.84$3.11
Low$2.52$2.63$2.84
High$2.77$3.19$3.38
Analysts (Rev / EPS)13 / 1113 / 116 / 2
Quarterly
MetricQ4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028Q3 2028
Revenue Avg$1.55B$2.67B$1.41B$1.54B$1.59B$2.75B$1.38B$1.38B
Low$1.53B$2.64B$1.39B$1.52B$1.57B$2.71B$1.36B$1.36B
High$1.59B$2.73B$1.44B$1.57B$1.63B$2.81B$1.41B$1.41B
EBITDA Avg$348M$601M$318M$346M$359M$618M$310M$310M
Low$344M$593M$314M$342M$354M$610M$306M$306M
High$357M$614M$325M$354M$367M$632M$317M$317M
EBIT Avg$291M$502M$266M$289M$300M$517M$259M$259M
Low$287M$495M$262M$285M$296M$510M$256M$256M
High$298M$513M$271M$296M$306M$528M$265M$265M
Net Income Avg$52M$370M$80M$56M$57M$384M$85M$64M
Low$38M$364M$79M$55M$56M$377M$84M$63M
High$64M$381M$82M$58M$58M$394M$88M$66M
EPS Avg$0.26$1.83$0.40$0.28$0.28$1.90$0.42$0.32
Low$0.19$1.80$0.39$0.27$0.27$1.87$0.42$0.31
High$0.32$1.88$0.41$0.29$0.29$1.95$0.43$0.33
Analysts (Rev / EPS)11 / 127 / 510 / 55 / 55 / 57 / 104 / 104 / 10

Earnings Surprises

Recent Analyst Actions

Jul 28, 2026Jefferies
Bath & Body Works price target raised to $23 from $22 at Jefferies
Target:$23.00
+12.2%from $20.49
Jul 8, 2026Goldman Sachs
Bath & Body Works downgraded to Sell from Neutral at Goldman Sachs
Target:$19.00
-7.9%from $20.62
Jul 6, 2026Morgan Stanley
Bath & Body Works resumed with an Equal Weight at Morgan Stanley
Target:$22.00
+3.4%from $21.27
Jun 23, 2026Wells Fargo
Bath & Body Works price target raised to $26 from $25 at Wells Fargo
Target:$26.00
+32.5%from $19.63
May 28, 2026Telsey Advisory
Bath & Body Works price target lowered to $22 from $25 at Telsey Advisory
Target:$22.00
+10.2%from $19.97
May 28, 2026Goldman Sachs
Bath & Body Works price target lowered to $23 from $26 at Goldman Sachs
Target:$23.00
+18.3%from $19.45
May 28, 2026Barclays
Bath & Body Works price target lowered to $23 from $25 at Barclays
Target:$23.00
+18.3%from $19.45
May 20, 2026UBS
Bath & Body Works price target lowered to $19 from $22 at UBS
Target:$19.00
+14.5%from $16.60
May 15, 2026Piper Sandler
Bath & Body Works assumed with a Neutral at Piper Sandler
Target:$20.00
+11.4%from $17.95
Feb 23, 2026UBS
Bath & Body Works price target raised to $22 from $21 at UBS
Target:$22.00
-2.4%from $22.55
Jan 14, 2026Jefferies
Bath & Body Works assumed with a Hold at Jefferies
Target:$24.00
+4.4%from $22.98
Jan 8, 2026Deutsche Bank
Bath & Body Works resumed with a Hold at Deutsche Bank
Target:$21.00
-6.8%from $22.53
Jan 8, 2026UBS
Bath & Body Works price target raised to $21 from $17 at UBS
Target:$21.00
-4.3%from $21.95
Jan 6, 2026Barclays
Bath & Body Works price target raised to $20 from $18 at Barclays
Target:$20.00
-1.1%from $20.23
Dec 17, 2025Robert W. Baird
Bath & Body Works price target raised to $20 from $19 at Baird
Target:$20.00
+1.5%from $19.70
Nov 24, 2025New Street
Bath & Body Works Inc. (BBWI) PT Lowered to $26 at BofA Securities
Target:$26.00
+75.1%from $14.85
Nov 21, 2025UBS
Bath & Body Works price target lowered to $17 from $32 at UBS
Target:$17.00
+7.5%from $15.82
Nov 21, 2025Wells Fargo
Bath & Body Works price target lowered to $25 from $33 at Wells Fargo
Target:$25.00
+58.0%from $15.82
Nov 21, 2025Telsey Advisory
Bath & Body downgraded to Market Perform from Outperform at Telsey Advisory
Target:$17.00
+7.5%from $15.82
Nov 21, 2025Barclays
Bath & Body Works price target lowered to $18 from $28 at Barclays
Target:$18.00
+13.8%from $15.82
Nov 21, 2025Morgan Stanley
Bath & Body Works downgraded to Equal Weight from Overweight at Morgan Stanley
Target:$18.00
+13.8%from $15.82
Nov 20, 2025Goldman Sachs
Bath & Body Works downgraded to Neutral from Buy at Goldman Sachs
Target:$17.00
+7.5%from $15.82
Nov 20, 2025Robert W. Baird
Bath & Body Works downgraded to Neutral from Outperform at Baird
Target:$19.00
+20.1%from $15.82
Oct 27, 2025Wells Fargo
Bath & Body Works price target lowered to $33 from $44 at Wells Fargo
Target:$33.00
+22.2%from $27.00
Oct 20, 2025Barclays
Bath & Body Works price target lowered to $28 from $32 at Barclays
Target:$28.00
+5.7%from $26.50
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.